THRB and metabolic dysfunction-associated steatohepatitis: Resmetirom, a liver-selective oral THR-β agonist, has recently been conditionally approved by the FDA for the treatment of significant and advanced fibrosis due to MASH without cirrhosis, using a weight-based oral daily dose of either 80 mg or 100 mg.